{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T20:14:31Z","timestamp":1793304871987,"version":"4.5.0"},"reference-count":0,"publisher":"American Society of Hematology","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>Concurrent administration pembrolizumab with chemotherapy in untreated classical Hodgkin lymphoma (CHL) has not previously been studied. To investigate this combination, we conducted a single arm study of concurrent pembrolizumab with AVD (APVD) for untreated CHL. We enrolled 30 patients (6 early favorable, 6 early unfavorable, and 18 advanced stage, median age 33 years (range 18-69 years)) and met the primary safety endpoint with no observed significant treatment delays in the first two cycles. Twelve patients experienced grade 3-4 non-hematologic adverse events (AEs) most commonly febrile neutropenia (5, 17%) and infection\/sepsis (3, 10%). Grade 3-4 immune-related AEs were seen in 3 patients, including ALT elevation (3, 10%) and AST elevation (1, 3%). One patient experienced an episode of grade 2 colitis and arthritis. Six (20%) patients missed at least one dose of pembrolizumab due to adverse events, primarily grade 2 or higher transaminitis (5, 17%). Among 29 response-evaluable patients, the best overall response rate was 100% and CR rate of 90%. With median follow up of 2.1 years, 2-year progression-free survival (PFS) and overall survival were 97% and 100%, respectively. To date, no patient who withheld or discontinued pembrolizumab due to toxicity has progressed. Clearance of ctDNA was associated with superior PFS when measured after cycle 2 (p=0.025) and at end of treatment (EOT, p=0.0016). None of the 4 patients with persistent disease by FDG-PET at EOT yet negative ctDNA have relapsed to date. Concurrent APVD shows promising safety and efficacy, but may yield spurious PET findings in some patients. Trial Registration Number: NCT03331341<\/jats:p>","DOI":"10.1182\/blood.2022019254","type":"journal-article","created":{"date-parts":[[2023,3,13]],"date-time":"2023-03-13T21:03:56Z","timestamp":1678741436000},"update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":19,"title":["Concurrent pembrolizumab with AVD for untreated classical Hodgkin lymphoma"],"prefix":"10.1182","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6703-0894","authenticated-orcid":false,"given":"Ryan C","family":"Lynch","sequence":"first","affiliation":[{"name":"Fred Hutch Cancer Center, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaitra S","family":"Ujjani","sequence":"additional","affiliation":[{"name":"University of Washington, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Poh","sequence":"additional","affiliation":[{"name":"University of Washington, Seattle, Washington, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9570-2755","authenticated-orcid":false,"given":"Edus H","family":"Warren","sequence":"additional","affiliation":[{"name":"University of Washington, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5354-7593","authenticated-orcid":false,"given":"Stephen D","family":"Smith","sequence":"additional","affiliation":[{"name":"University of Washington, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3365-6562","authenticated-orcid":false,"given":"Mazyar","family":"Shadman","sequence":"additional","affiliation":[{"name":"University of Washington, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian G.","family":"Till","sequence":"additional","affiliation":[{"name":"University of Washington, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikram","family":"Raghunathan","sequence":"additional","affiliation":[{"name":"University of Washington, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Alig","sequence":"additional","affiliation":[{"name":"Stanford University, Stanford, California, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5153-5625","authenticated-orcid":false,"given":"Ash A","family":"Alizadeh","sequence":"additional","affiliation":[{"name":"Stanford University School of Medicine, Stanford, California, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5264-951X","authenticated-orcid":false,"given":"Avanti","family":"Gulhane","sequence":"additional","affiliation":[{"name":"University of Washington, Seattle, Washington, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0150-5401","authenticated-orcid":false,"given":"Delphine","family":"Chen","sequence":"additional","affiliation":[{"name":"University of Washington, Seattle, Washington, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yolanda","family":"Tseng","sequence":"additional","affiliation":[{"name":"Fred Hutch Cancer Center, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilary","family":"Coye","sequence":"additional","affiliation":[{"name":"University of Washington, Seattle, Washington, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Shelby","sequence":"additional","affiliation":[{"name":"University of Washington, Seattle, Washington, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Ottemiller","sequence":"additional","affiliation":[{"name":"University of Washington, Seattle, Washington, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarith","family":"Keo","sequence":"additional","affiliation":[{"name":"University of Washington, Seattle, Washington, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaitlin","family":"Verni","sequence":"additional","affiliation":[{"name":"University of Washington, Seattle, Washington, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyan","family":"Du","sequence":"additional","affiliation":[{"name":"University of Washington, Seattle, Washington, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacquelin","family":"Vandermeer","sequence":"additional","affiliation":[{"name":"University of Washington\/Seattle Cancer Care Alliance, Seattle, Washington, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Gaston","sequence":"additional","affiliation":[{"name":"University of Washington, Fred Hutchinson Cancer Center, Seattle, Washington, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Rasmussen","sequence":"additional","affiliation":[{"name":"Fred Hutch Cancer Center, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Martin","sequence":"additional","affiliation":[{"name":"UNIVERSITY OF WASHINGTON, SEATTLE, Washington, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edmond","family":"Marzbani","sequence":"additional","affiliation":[{"name":"University of Washington, Seattle, Washington, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"MPH","given":"Jenna M","family":"Voutsinas","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Research Center, Seattle, Washington, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay K","family":"Gopal","sequence":"additional","affiliation":[{"name":"Fred Hutch Cancer Center, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,3,13]]},"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/doi\/10.1182\/blood.2022019254\/2038146\/blood.2022019254.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/doi\/10.1182\/blood.2022019254\/2038146\/blood.2022019254.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,13]],"date-time":"2023-03-13T21:03:58Z","timestamp":1678741438000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/doi\/10.1182\/blood.2022019254\/494889\/Concurrent-pembrolizumab-with-AVD-for-untreated"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,13]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1182\/blood.2022019254","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,13]]},"article-number":"blood.2022019254"}}